2026 Guide to DSO Practice Multiples and EBITDA Ranges

Key Takeaways

• DSO demand remains strong in 2026, but the spread between top-tier and middle offers has widened, so preparation can be the key to maximizing value.
• Normalized EBITDA is the central valuation metric. Proper add-backs can increase reported EBITDA by 15–40% and can translate into hundreds of thousands or millions in sale proceeds.
• 2026 EBITDA multiples range from 5×–8× for single-doctor add-ons to 10×–12×+ for platform-grade groups. Specialty practices and strong fee-for-service payer mixes often command premiums.
• Deal structures commonly include 60–85% cash at close, 10–30% rollover equity, and 1–3 year earnouts. Careful modeling of after-tax cash and risk across several time horizons can help owners compare offers.
• McLerran & Associates guides sellers through competitive auctions that generate multiple offers and can deliver materially higher valuations. Schedule a free, confidential discovery call to see how a structured process may improve your outcome.

Normalized EBITDA as the Foundation of DSO Valuations

Normalized EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reflects a dental practice’s recurring operating profitability after removing non-cash accounting items and owner-specific or one-time expenses. Buyers use this single number to anchor valuation offers. The calculation typically looks like this:

Normalized EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization + Owner Compensation Adjustment + Personal Expense Add-Backs + One-Time Cost Add-Backs − One-Time Revenue Items +/− Rent Normalization

Many owners run personal expenses through the business and pay themselves above or below a market-rate replacement salary. As a result, normalization can add 15–40% to reported EBITDA. That increase can translate into hundreds of thousands or even millions of dollars in enterprise value.

2026 EBITDA Multiple Ranges by Practice Size

EBITDA multiples in dental DSO transactions fall into ranges, not fixed points. Practice size, specialty, payer mix, associate depth, and buyer competition can be some of the main factors that shape those ranges. The table below presents 2026 market ranges drawn from McLerran & Associates transaction data and corroborated by multiple independent market sources. All figures represent adjusted (normalized) EBITDA multiples paid by institutional buyers, not private individual buyers.

Practice Tier	Adjusted EBITDA Level	Typical Buyer Type	2026 Multiple Range
Single-doctor add-on	Typically under $1M	Small or regional DSO tuck-in	5×–8×
Associate-led regional add-on	Often $1M–$3M	Regional DSO add-on	7×–9×
Emerging multi-location platform	$3M–$5M	Strategic or PE platform acquirer	9×–11×
Platform-grade group	$5M+	PE platform buyer	10×–12×+

Specialty practices such as oral and maxillofacial surgery, orthodontics, and pediatric dentistry can command a premium over general dentistry at similar size tiers. Oral and maxillofacial surgery often attracts the strongest demand and highest multiples, while general dentistry still earns aggressive, near-all-time-high valuations. Payer mix can move a practice’s position within its band by 1–2 turns. Fee-for-service dominant practices tend to sit near the top of the range, while Medicaid-heavy practices often land near the bottom.

One multiplier point can matter enormously in dollar terms. On $800,000 of adjusted EBITDA, a single turn of the multiple equals $800,000 of enterprise value. Controlling the inputs, especially the normalized EBITDA number and the sales process, can be some of the highest-impact work a seller undertakes.

How a CPA Team Builds Normalized EBITDA

The normalization process usually starts with tax returns, profit and loss statements, and trailing twelve-month financials. A CPA-led team then reconstructs true profitability by applying documented add-backs. Common add-back categories in dental practice valuations include:

• Owner compensation adjustment: The owner’s actual pay is replaced with a market-rate replacement-doctor salary. For general dentistry, this is typically 30% of the owner’s clinical production. For specialists, it often ranges from 35–50%. If an owner pays themselves $600,000 and the market replacement cost is $250,000, then $350,000 is added back.
• Personal vehicle expenses: Often 80–100% personal use, added back with documentation.
• Owner life insurance premiums and above-market retirement contributions that benefit the owner personally.
• Personal travel, club memberships, and meals and entertainment that are personal rather than operational.
• Non-arm’s-length family payroll above market rates for the actual duties performed.
• One-time, non-recurring costs such as extraordinary legal fees, one-time repairs, or transaction preparation expenses.
• Rent normalization: When the owner also owns the building, rent is adjusted to a market rate, typically 5–8% of collections, which can create either a positive or negative adjustment.

A defensible EBITDA bridge relies on documentation tied to general ledger detail, payroll records, leases, and invoices. Buyers frequently reject unsupported add-backs during DSO diligence. McLerran & Associates therefore builds valuations to a diligence-grade standard from the outset so the number can hold when a buyer’s quality-of-earnings team reviews it and the deal is less likely to be re-traded downward late in the process.

Cash, Rollover Equity, and Earnouts in 2026 Deals

The headline multiple only tells part of the story. DSO deals are rarely all-cash. In 2026, a common structure includes 60–85% cash at close, 10–30% rollover equity in the DSO’s holding company, and a 1–3 year earnout tied to post-close EBITDA maintenance.

Each component carries a different risk profile, and understanding that risk can be essential when comparing offers. Cash at close is immediate and certain, so it is usually the most valuable dollar in the deal. Rollover equity, sometimes called the “second bite of the apple,” is an ownership stake in the acquiring DSO’s parent company. It can offer upside if the DSO grows and recapitalizes at a higher multiple, but it is illiquid, junior to preferred equity, and exposed if the DSO underperforms. As much as 10–30% of a platform deal can be in rollover equity.

Earnouts are contingent payments tied to post-close financial targets. Only 50–60% of earnouts pay out in full, because after closing, the buyer controls expenses, headcount, and pricing, which all affect whether targets are achievable. Since these three components differ so much in timing and risk, McLerran & Associates models each deal across 3-, 5-, 7-, and 10-year horizons. The firm compares real after-tax cash across structures so owners can see what a deal may actually be worth, not just what the headline number suggests. Many DSO deals receive long-term capital gains treatment on a large portion of proceeds, which can significantly affect net outcomes. A qualified tax advisor can provide guidance specific to each owner’s situation.

Practice Traits That Can Lift Your Multiple

Within any size tier, a practice’s position inside the multiple range often comes down to measurable and mostly controllable factors. Owners who understand these levers before going to market can be better prepared to defend and potentially expand their valuation.

• Associate depth: Owner-performed production below 70% of total chair time often supports the upper end of the range, because revenue appears more transferable and less dependent on one doctor.
• Hygiene productivity: Hygiene revenue above roughly 30% of collections signals recurring, transferable patient revenue and can earn a premium multiple.
• Payer mix: Fee-for-service collections of 60% or more often support full or premium multiples. Medicaid exposure of 50% or more can compress multiples by 15–25%.
• Management infrastructure: A trained, non-owner management team can add 1–3 turns to EBITDA multiples by reducing personal goodwill and key-person risk.
• Geographic market: Practices in high-growth metros can command a 0.5–1× EBITDA premium over rural or slow-growth markets.
• Competitive tension: Multiple qualified buyers at the table can be the single most powerful lever. A seller negotiating with one DSO has limited leverage, while a seller with several competing offers has far more.

McLerran & Associates has guided roughly 2,000 successful practice sales and evaluated more than 10,000 practices. This experience gives the firm a detailed view of which levers tend to matter most in each specialty and market.

Single Offer Compared With a Structured Auction

A practice owner who accepts the first DSO offer usually negotiates from the weakest position. DSOs that negotiate deals every week know what practices typically command and have strong incentives to anchor price and terms as low as they reasonably can. An owner selling once in a career often lacks comparable data and has no built-in competitive pressure.

A structured auction can change that dynamic. McLerran & Associates runs a 45–60 day competitive bid process with a vetted pool of well-qualified buyers, using the same approach that creates competitive tension around price and terms. Advisor-led positioning and diligence quality matter more in 2026 than in prior years, because the spread between the best and worst offers on a given practice has widened. The process usually narrows from initial offers to in-person meetings with the top one to three finalists, which can give the seller both stronger pricing and a real choice of partner.

Transaction statistics highlight the difference. Do-it-yourself close rates often run around 15–20%. A well-run brokered process can close at roughly 80%. McLerran & Associates reports a transaction rate of approximately 85–90% among its clients, compared with an industry norm closer to 35–40%.

Schedule a free, confidential discovery call with McLerran & Associates to explore how a structured auction process could affect your outcome.

Red Flags in DSO Term Sheets

Not every offer deserves serious consideration. Owners can watch for several warning signs in DSO term sheets and letters of intent:

• Punitive earnout structures: All-or-nothing earnouts with no pro-rata provision mean a near-miss on an EBITDA target pays nothing. McLerran & Associates often negotiates for pro-rata catch-up provisions and later start dates to account for integration disruption.
• Undercapitalized buyers: The DSO market has become more disciplined, but weaker buyers remain active. A DSO that cannot demonstrate profitable unit economics across its existing offices, or whose private equity backer lacks a track record of successful exits, can create real risk for the rollover equity portion of the deal.
• Equity rollover risk: Rollover equity usually sits as junior common equity behind the buyer’s preferred equity with liquidation preferences. The value realized at a future exit can be substantially lower than the headline rollover percentage suggests.
• Vague post-close support commitments: A DSO that cannot specify what it will provide after closing, such as compliance, HR, payroll, IT, marketing, or growth capital, may not deliver the operational support the seller expects.

McLerran & Associates maintains a vetted buyer pool and has blacklisted DSOs known for poor post-close environments so sellers do not encounter those buyers at the table.

Readiness Checklist Before You Engage DSOs

Owners can benefit from working through several questions before engaging any advisor or responding to any DSO inquiry:

1. What is my primary motivation, such as liquidity, growth capital, succession, or operational relief?
2. What is my minimum acceptable cash at close, and how much equity risk am I willing to carry?
3. How long am I willing to continue working post-close, and under what clinical autonomy conditions?
4. What do I want for my staff and patients after the transition?
5. Do I have 3–5 years of clean, reconciled financials that a buyer’s quality-of-earnings team can trace?
6. Has my owner compensation been documented and benchmarked to market rates?
7. Do I know my practice’s normalized EBITDA, meaning the defensible, add-back-supported figure a DSO will actually use?
8. Have I compared the DSO path against the private-buyer path with real numbers, not assumptions?

If the answer to the last three questions is no, you are effectively negotiating without instruments. Without a defensible normalized EBITDA and clean financials, it becomes very difficult to judge whether any offer is fair. A diligence-grade valuation completed before any DSO conversation can give owners a clearer baseline and more confidence in negotiations.

Next Steps for Practice Owners in 2026

In 2026, the difference between a good outcome and a great one often comes down less to the market and more to preparation, process, and representation. Owners who control the narrative around normalized EBITDA, run a competitive process among vetted buyers, and understand the economics of cash, equity, and earnout structures can realize stronger outcomes than those who accept a single offer.

McLerran & Associates is the nation’s largest dental-specific sell-side M&A advisory firm, with roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and a team carrying over 100 years of collective dental-industry experience. The firm works exclusively on the sell side, so its only client is the practice owner.

Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and your options. Call (512) 900-7989, email info@dentaltransitions.com, or schedule your call online.

Owners who are not ready to sell yet can still prepare. Join the McLerran M&A Summit on October 29–30, 2026, a dental-only event built for owners who have not decided yet. Attendees earn 4 CE credits and receive a complimentary practice valuation (a $2,500 value). The summit covers deal structures, EBITDA mechanics, and the current DSO landscape so owners can learn the basics before committing to any path.

Frequently Asked Questions

What does “normalized EBITDA” mean for a dental practice, and why does it matter more than net income?

Net income on a dental practice’s tax return is usually structured to minimize taxes, not to showcase profitability. Many owners design their books to reduce taxable income, which can significantly understate what the practice truly earns. Normalized EBITDA corrects for this by adding back personal expenses, adjusting owner compensation to a market-rate replacement salary, and removing one-time costs and revenues. The result is a number that reflects what a new owner or DSO could reasonably expect the practice to earn under standard conditions. Because DSOs multiply this figure by their target multiple to arrive at enterprise value, a $100,000 error in normalized EBITDA can translate into $700,000 to $1,000,000 or more in sale proceeds at typical 2026 multiples. A CPA-led, diligence-grade normalization with every add-back documented and traceable can form the foundation of a valuation that is more likely to hold during buyer diligence.

How do I know whether to sell to a DSO or a private buyer?

The right path can depend on practice size and profitability, personal goals, and timeline. Smaller premier practices, roughly $1 million to $1.5 million in revenue, often fit a doctor-to-doctor sale where the buyer is another dentist and the transaction is simpler. Larger practices, especially those above $1.5 million in revenue with associate depth and scalable infrastructure, tend to attract stronger DSO interest and can command higher multiples than a private buyer would typically pay. Practices in the $1.5 million to $3 million revenue range can often go either direction, so a side-by-side comparison of real numbers can be helpful. Because McLerran & Associates works both paths in roughly equal measure, the firm prepares a side-by-side valuation so owners can compare expected value and long-term economics on each path before deciding.

What is rollover equity, and should I be concerned about it?

Rollover equity is the portion of a DSO deal paid not in cash but in an ownership stake in the acquiring DSO’s parent holding company. Many owners call it the “second bite of the apple” because if the DSO grows and is later recapitalized or sold at a higher multiple, the retained equity can increase in value. Rollover equity also carries real risk. It is illiquid, so owners generally cannot sell it until the DSO exits. It also sits behind the buyer’s preferred equity in the capital structure, which means preferred investors get paid first in any exit. If the DSO underperforms or exits at a lower multiple than expected, the rollover equity may be worth less than the headline percentage suggests. As much as 10–30% of a platform-level deal can be in rollover equity. McLerran & Associates therefore helps owners evaluate the DSO like an investment, reviewing its profitability, growth trajectory, management team, and the track record of its private equity backer before accepting any equity component.

Why does running a competitive process matter if I already have a strong offer?

A single offer, even one that appears strong, lacks competitive context. Without testing the market, it is difficult to know whether that offer reflects the best combination of price and terms available. DSOs negotiate acquisitions every week and often anchor valuations at the lowest defensible number. A structured auction, where multiple vetted buyers compete at the same time, can create the tension that pushes both price and terms upward. Competition can also improve non-price terms, such as making earnouts less punitive, equity provisions more favorable, and post-close autonomy commitments more specific when buyers know other qualified bidders are at the table.

What makes a dental practice command the upper end of its multiple range?

Several factors can position a practice at the top of its size tier’s multiple range rather than the middle or bottom. Associate depth often ranks among the most significant. When the owner performs less than 70% of total production, revenue appears more transferable and buyers tend to discount key-person risk less. Hygiene productivity above roughly 30% of collections signals a strong, recurring patient base. A fee-for-service dominant payer mix usually supports premium multiples, while significant Medicaid exposure can compress them. A trained management layer, such as office managers, clinical coordinators, or a practice administrator who can operate without the owner, can remove personal goodwill from the valuation and add meaningful turns to the multiple. Clean, well-documented financials that hold up under buyer scrutiny can also prevent re-trading. Geographic location in a high-growth metro market can add a further premium over rural or slow-growth areas. Many of these factors are at least partly controllable, so preparation that begins years before any DSO conversation can have a meaningful impact on eventual value.